MGI Misses

MGI Pharma Inc. (MOGN) widely missed expectations with second quarter losses of 25 cents per share compared with earnings of 17 cents per share a year earlier. Upcoming competition from a generic version of MGI's Aloxi prompted the biopharmaceutical firm to trim its full year forecast. The stock price plummeted $6.89 to close at $14.54.